Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. Under a mutual ...

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the first to ...

Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk ...

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive, ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...

LONDON (Reuters) - Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive ...

May 16 - Novo Nordisk (NYSE:NVO) said CEO Lars Fruergaard Jrgensen will step down after eight years at the helm, following a sharp decline in its share price over the past year. Shares of the ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.